2014至2018年麻疹病例分类:对中国消除麻疹进展的启示
研究分析2014—2018年中国麻疹监测系统报告的121969例实验室确诊麻疹病例,按疫苗接种状态分类。未接种含麻疹成分疫苗的2岁以下儿童和接种史不详的20岁以上成人占多数;有接种信息的77384例中42425例(34.78%)为程序上可预防。作者认为现行免疫规划有效,建议未来聚焦8—23月龄未接种婴幼儿和接种史不详的20岁以上高风险成人。
要点
- 2014—2018年121969例实验室确诊麻疹中,未接种疫苗的2岁以下儿童44424例(36.42%)和接种史不详的20岁以上成人37564例(30.80%)占多数。
- 有接种信息的77384例中,42425例(34.78%)为程序上可预防,其中38840例(91.55%)为≥8月龄且无含麻疹成分疫苗接种史。
- 34959例(28.66%)为程序上不可预防,包括22611例(64.68%)因年龄过小无法接种首剂、6857例(19.61%)已接种首剂但年龄过小无法接种第二剂、5491例(15.71%)已接种至少两剂。
核心结论
- 研究确认中国大陆现行麻疹免疫规划在降低麻疹发病率方面有效。
- 作者认为未来中国麻疹免疫活动的重点人群应为8—23月龄未接种疫苗的婴幼儿和接种史不详的20岁以上高风险易感成人。
研究设计与样本
- 研究分析了2014—2018年麻疹监测系统(MSS)报告的121969例实验室确诊麻疹病例,按疫苗接种状态进行分类。
主要发现
- 未接种含麻疹成分疫苗的2岁以下儿童44424例(占全部病例36.42%)和接种史不详的20岁以上成人37564例(占全部病例30.80%)占2014—2018年麻疹病例的大多数。
- 有接种信息的77384例中,42425例(34.78%)为程序上可预防,其中38840例(91.55%)为≥8月龄且无含麻疹成分疫苗接种史。
- 34959例(28.66%)为程序上不可预防,其中22611例(64.68%)因年龄过小无法接种首剂含麻疹成分疫苗,6857例(19.61%)已接种首剂但年龄过小无法接种第二剂,5491例(15.71%)已接种至少两剂含麻疹成分疫苗。
- 121969例中15933例(13.06%)有含麻疹成分疫苗接种史。
- 有含麻疹成分疫苗接种史的病例中,麻疹病毒感染主要发生在接种后第一个月内,尤其是接种一剂麻疹疫苗者。
临床怎么用
- 作者认为未来中国麻疹免疫活动的重点人群应为8—23月龄未接种疫苗的婴幼儿和接种史不详的20岁以上高风险易感成人。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measles incidence has decreased dramatically in China due to the implement of measles-containing vaccine (MCV). However, a measles epidemic caused resurgence recently, even among vaccinated individuals. To evaluate the effectiveness of current immunization programs and discuss initiatives for the next step in measles elimination in mainland China, the characteristics of 121,969 laboratory-confirmed measles cases reported in the measles surveillance system (MSS) during 2014-2018 were analyzed according to the vaccination status of the cases in this study. Children under 2 years of age without MCV vaccination (44,424, 36.42% of all cases) and adults over 20 years of age with an unknown vaccination history (37,564, 30.80% of all cases) accounted for the majority of measles cases from 2014 to 2018. 42,425 (34.78%) of the 77,384 cases with available vaccination information were categorized as programmatically preventable. 38,840 (91.55%) of the 42,425 cases were aged ≥8 months without the MCV vaccination history. 34,959 (28.66%) cases were categorized as programmatically non-preventable, of whom 22,611 (64.68%) were too young to receive their first MCV dose, 6857 (19.61%) received their first dose and were too young to receive their second dose, 5491 (15.71%) received at least two doses of MCV. 15,933 (13.06%) of the 121,969 cases had a history of MCV vaccination. Measles virus infection in cases with an MCV vaccination history mainly occurred within the first month after MCV vaccination, especially in those who received a one-dose measles vaccination. MCV vaccination could reduce the frequencies of clinical symptoms and complications of measles cases. Our study confirmed that the current measles immunization programs used in mainland China is effective in reducing the measles incidence in China. Unvaccinated infants/children aged 8-23 months and high risk susceptible adults over 20 years of age with unknown vaccination histories should be the focus groups of measles immunization activities in China in the future.
引用
- Cui A, Zhang Y, Zhu Z, et al. Classification of measles cases from 2014 to 2018: Implications for progress towards measles elimination in China. Vaccine. 2020. PMID: 32280040. doi:10.1016/j.vaccine.2020.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。